Bionano Announces Presentations Featuring OGM Utility Across Blood Cancer Research at the American Society of Hematology (ASH) Annual Meeting
06 Décembre 2023 - 2:00PM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that
the American Society of Hematology (ASH) Annual Meeting and
Exposition 2023 will feature a broad range of content covering
OGM’s utility for research in areas including myeloid cancer,
hematological malignancy, leukemia and blood disorders.
ASH’s Annual Meeting brings together industry, medical, and
academic professionals to discuss advances in the field of blood
disease. The ASH conference will be held December 9-12,
2023, in San Diego, California and online.
Dr. Enze Liu from Indiana University Medical Center will present
findings from a research study utilizing OGM to detect complex SVs
in plasma cells that may be associated with disease progression in
multiple myeloma (MM) as part of a session titled “Multiple Myeloma
and Plasma Cell Dyscrasias: Basic and Translational: Molecular
Characterization of MM and Precursor Disease States.” The
presentation will take place Sunday, December 10, 2023, at 5:30 pm
PT at the Manchester Grand Hyatt Harbor Ballroom.
13 posters featuring results from OGM applications in
cytogenetic research will be presented at the conference. Unless
otherwise noted below, posters will be available to view at the
Manchester Grand Hyatt Harbor Ballroom. Posters displayed at the
conference may also be viewed here; online only posters may be
viewed here.
Scientific presentations and poster sessions from Bionano and
collaborators include:
Poster Number |
Title |
Author |
Presented |
1414 |
Partner Gene Associated Trinary Fusion and Orchestration of
Multiple Molecular Events in Acute Promyelocytic Leukemia with
Variant Rara Fusion Genes |
Chen J. |
December 9, 20235:30-7:30 PM PT |
1610 |
Deciphering the Structural Variants in B Cell Acute Lymphoblastic
Leukemia by Optical Genome Mapping |
Liu M. |
December 9, 20235:30-7:30 PM PT |
2834 |
Optical Genome Mapping for Genome-Wide Structural Variation
Analysis in Hematologic Malignancies: A Prospective Study
Demonstrates Additional Findings Compared to Standard-of-Care (SOC)
Cytogenomic Methods |
Wicks S. |
Halls G-H, San Diego Convention CenterDecember 10, 20236:00-8:00 PM
PT |
4116 |
Multiomic Characterization of Myelodysplastic Neoplasms (MDS) with
Micromegakaryocytes Highlights the Role of EZH2-RUNX1 Deregulation
in Disease Hysiopathology and Response to Targeted Therapies Author
Links Open Overlay Panel |
Fernandez-Serrano M. |
December 11, 20236:00-8:00 PM PT |
4303 |
Optical Genomic Mapping Provides Unique Findings in Various Types
of Myeloid Neoplasms |
Quesada A. |
December 11, 20236:00-8:00 PM PT |
4612 |
Comprehensive Characterization of Evolution of Genomic Complexity
by Structural Variant and Mutational Profiling in Myelodysplastic
Syndrome Patients with Hypomethylating Agent Failure |
Kanagal-Shamanna R. |
December 11, 20236:00-8:00 PM PT |
5024 |
Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome
Mapping in the Laboratory Routine |
Díaz-González Á. |
December 11, 20236:00-8:00 PM PT |
5038 |
Optical Genome Mapping Allows Detection and Characterization of
Cytogenetically Cryptic Oncogenic Fusions in Pediatric Acute
Myeloid Leukemia |
Raca G. |
December 11, 20236:00-8:00 PM PT |
5039 |
Assessment of Optical Genome Mapping for Front-Line Diagnostic
Evaluation of Acute Leukemia: A Canadian Single-Center Evaluation
of Added Yield in 69 Informative Cases |
McGinnis E. |
December 11, 20236:00-8:00 PM PT |
|
Optical Genome Mapping Combined with High-Throughput Sequencing Is
Effective for the Diagnostic and Prognostic Genomic Classification
of Acute Myeloid Leukemia and Myelodysplastic Neoplasms |
Bris Y. |
Online publication |
|
Platinum Talen-Mediated Knock-in of Single-Stranded DNA Templates
Facilitates Manufacturing of Clinical-Scale Non-Virally Gene-Edited
T Cells from Peripheral Blood |
Toishigawa K. |
Online publication |
|
Optical Genome Mapping Provides New Molecular Insights in High-Risk
Mantle Cell Lymphoma: A Lysa Study |
Kaltenbach S. |
Online publication |
|
Deciphering the Structural Variants in Acute Myeloid Leukemia and
Myelodysplastic Neoplasms by Optical Genome Mapping |
Liu M. |
Online publication |
Session |
Title |
Presenter/s |
Presented |
Platform Presentation |
Unraveling Diverse Mechanisms of Complex Structural Variant
Interactions through Multiomic Data in Multiple Myeloma |
Liu E. |
Harbor Ballroom, Manchester Grand HyattDecember 10, 20235:30 PM
PT |
“The broad range of presentations on the use of OGM for
hematological malignancy research at ASH this year illustrate the
importance of OGM in an area of medical research that can really
improve patient care in the long run. The ASH conference brings
together thousands of clinicians, scientists and industry members
working to conquer blood diseases, and we are pleased that OGM and
its role in these research areas will be so well-represented at the
meeting,” stated Erik Holmlin, PhD, president and chief
executive officer of Bionano.
More details on the conference can be found here.
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
The Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. The Company additionally offers
nucleic acid extraction and purification solutions using
proprietary isotachophoresis (ITP) technology. For more
information,
visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Unless specifically identified, Bionano’s OGM products are for
research use only and not for use in diagnostic procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “potential,” “will,” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
OGM’s utility for research applications in myeloid cancer,
hematological malignancy, leukemia and blood disorders, and the
utility of OGM for research in the areas reported in the
presentations given and the posters made available at ASH’s 2023
annual meeting, and the growth and adoption of OGM for use in
research applications in myeloid cancer, hematological malignancy,
leukemia and blood disorders. Each of these forward-looking
statements involves risks and uncertainties. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with:
global and macroeconomic events, such as recent and potential bank
failures, potential resurgences of COVID-19 or other pandemic
inducing diseases, the ongoing conflicts between Ukraine and
–Russian and Israel and Hamas and related sanctions,, on our
business and the global economy; general market conditions; changes
in the competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; failure of
OGM to be adopted or to prove useful for research in areas
including applications in myeloid cancer, hematological malignancy,
leukemia and blood disorders; the ability of our OGM solutions to
offer the anticipated benefits for and contributions to the areas
reported in the presentations given and posters made available at
the ASH’s 2023 annual meeting; future study results contradicting
the results reported in the presentations given and posters made
available at the ASH’s 2023 annual meeting; changes in our
strategic and commercial plans; our ability to obtain sufficient
financing to fund our strategic plans and commercialization
efforts, our ability to effectively manage our uses of cash, and
our ability to continue as a “going concern”; the ability of
medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2022 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Bionano Genomics (NASDAQ:BNGO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024